32 patents
Utility
Peptide Inhibitors of INTERLEUKIN-23 Receptor and Their Use to Treat Inflammatory Diseases
22 Dec 22
The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
Chengzao Sun, Brian Troy Frederick, Sandeep Somani, Ashok Bhandari, Raymond Patch, Stephanie Barros, Raffaele Ingenito, Roberto Costante, Danila Branca, Elisabetta Bianchi
Filed: 14 Jan 21
Utility
Conjugated Hepcidin Mimetics
24 Nov 22
The present invention provides hepcidin analogues, and related pharmaceutical compositions and use thereof in treating polycythemia vera.
David Y. LIU, Gregory Thomas BOURNE, Roopa TARANATH, Suneel Kumar GUPTA, Nishit Bachulal MODI
Filed: 3 Sep 20
Utility
Hepcidin Analogues and Uses Thereof
3 Nov 22
The present invention relates, inter alia, to certain hepcidin peptide analogues, including peptides and dimers thereof, and to the use of the peptides and peptide dimers in the treatment and/or prevention of a variety of diseases, conditions or disorders, including treatment and/or prevention of iron overload diseases, which include hereditary hemochromatosis and iron-loading anemias, and other conditions and disorders described herein.
Mark Leslie SMYTHE, Gregory Thomas BOURNE, Simone VINK, Brian Troy FREDERICK, Praveen MADALA, Anne Pernille TOFTENG SHELTON, Jacob Ulrik FOG
Filed: 16 Nov 20
Utility
Analogues of hepcidin mimetics with improved in vivo half lives
18 Oct 22
The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
Gregory Thomas Bourne, Mark Leslie Smythe, Brian Troy Frederick, Ashok Bhandari
Filed: 1 Oct 20
Utility
Peptide Inhibitors of INTERLEUKIN-23 Receptor and Their Use to Treat Inflammatory Diseases
11 Aug 22
The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
Ashok BHANDARI, Brian Troy Frederick, David Clifford Sullivan
Filed: 13 Dec 21
Utility
Methods for Synthesizing Beta-homoamino Acids
16 Jun 22
Methods of making β-homoamino acids as intermediate for synthesis of peptide monmer and dimer α4β7-antagonists are disclosed.
Suresh Kumar MANTHATI, Ashok BHANDARI, Mohammad Reza MASJEDIZADEH
Filed: 27 Mar 20
Utility
Compositions of Peptide Inhibitors of INTERLEUKIN-23 Receptor
9 Jun 22
The present invention relates to compositions of peptide inhibitors of the interleukin-23 receptor (IL-23R) or pharmaceutically acceptable salt or solvate forms thereof, corresponding pharmaceutical compositions, methods and/or uses for treatment of autoimmune inflammation and related diseases and disorders.
Giustino Di Pretoro, Dajun SUN, Gopal RAJAN, Geraldine BROECKX, Nathalie MERTENS, Shu LI, Felix LAI, Mohammad MASJEDIZADEH
Filed: 19 Nov 21
Utility
NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
26 May 22
The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.
Ashok BHANDARI, Dinesh V. PATEL, Genet ZEMEDE, Larry C. MATTHEAKIS, David LIU
Filed: 16 Jul 21
Utility
Peptide Inhibitors of INTERLEUKIN-23 Receptor and Their Use to Treat Inflammatory Diseases
10 Feb 22
The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
Ashok Bhandari, Brian Troy Frederick, David Clifford Sullivan
Filed: 7 May 21
Utility
NOVEL a4B7 THIOETHER PEPTIDE DIMER ANTAGONISTS
2 Dec 21
The invention relates to thioether monomer and dimer peptide molecules which inhibit binding of α4β7 to the mucosal addressing cell adhesion molecule (MAdCAM) in vivo.
Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Brian Troy Frederick, Larry C. Mattheakis, David Liu
Filed: 29 Dec 20
Utility
Oral Peptide Inhibitors of INTERLEUKIN-23 Receptor and Their Use to Treat Inflammatory Bowel Diseases
25 Nov 21
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
Ashok BHANDARI, Gregory Thomas Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
Filed: 28 Jan 21
Utility
α4α7 peptide monomer and dimer antagonists
7 Sep 21
The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.
Ashok Bhandari, Dinesh V. Patel, Genet Zemede, Larry C. Mattheakis, David Liu
Filed: 4 Feb 20
Utility
Peptide Inhibitors of INTERLEUKIN-23 Receptor and Their Use to Treat Inflammatory Diseases
26 Aug 21
The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
Chengzao Sun, Brian Troy Frederick, Sandeep Somani, Gregory Thomas Bourne, Raymond Patch, Ashok Bhandari, Raffaele Ingenito, Roberto Costante, Danila Branca, Elisabetta Bianchi
Filed: 14 Jan 21
Utility
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
22 Jun 21
The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
Ashok Bhandari, Brian Troy Frederick, David Clifford Sullivan
Filed: 24 Aug 20
Utility
Analogues of Hepcidin Mimetics with Improved In Vivo Half Lifes
20 May 21
The present invention provides hepcidin analogues with improved in vivo half lives, and related pharmaceutical compositions and methods of use thereof.
Gregory Thomas Bourne, Mark Leslie Smythe, Brian Troy Frederick, Ashok Bhandari
Filed: 1 Oct 20
Utility
Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases
9 Mar 21
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel disease, are disclosed.
Ashok Bhandari, Gregory Thomas Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
Filed: 12 Dec 18
Utility
Conjugated Hepcidin Mimetics
4 Mar 21
The present invention provides hepcidin analogues, and related pharmaceutical compositions and use thereof in treating polycythemia vera.
David Y. Liu, Gregory Thomas Bourne, Roopa Taranath, Suneel Kumar Gupta, Nishit Bachulal Modi
Filed: 3 Sep 20
Utility
Peptide Inhibitors of INTERLEUKIN-23 Receptor and Their Use to Treat Inflammatory Diseases
14 Jan 21
The present invention provides novel peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases.
Ashok Bhandari, Brian Troy Frederick, David Clifford Sullivan
Filed: 24 Aug 20
Utility
NOVEL a4B7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
30 Sep 20
The invention relates to peptide dimer compounds and peptide monomer compounds that potently inhibit binding of α4β7 to the mucosal addressin cell adhesion molecule (MAdCAM) in vivo, possess high selectivity against α4β1 binding, and have high stability under gastrointestinal conditions.
Ashok BHANDARI, Dinesh V. PATEL, Genet Zemede, Larry C. Mattheakis, David Liu
Filed: 3 Feb 20
Utility
Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
28 Sep 20
Peptide inhibitors of the interleukin-23 receptor, and related compositions and methods of using these peptide inhibitors to treat or prevent a variety of diseases and disorders, including inflammatory bowel diseases, are described.
Ashok Bhandari, Gregory Bourne, Xiaoli Cheng, Brian Troy Frederick, Jie Zhang, Dinesh V. Patel, David Liu
Filed: 14 Jul 16